![Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors :: Adaptimmune (ADAP) Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors :: Adaptimmune (ADAP)](https://images.newsfilecorp.com/files/8845/136054_img1.jpg)
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors :: Adaptimmune (ADAP)
![Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial :: Adaptimmune (ADAP) Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial :: Adaptimmune (ADAP)](https://d1io3yog0oux5.cloudfront.net/_9d659c3069a4a717c877f78db7507911/adaptimmune/db/223/1247/social_image_resized.jpg)
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial :: Adaptimmune (ADAP)
![Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors :: Adaptimmune (ADAP) Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors :: Adaptimmune (ADAP)](https://images.newsfilecorp.com/files/8845/136054_c2382ad5a4767b4d_005.jpg)
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors :: Adaptimmune (ADAP)
![Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors | MD Anderson Cancer Center Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors | MD Anderson Cancer Center](https://www.mdanderson.org/images/newsroom/science/t-cells_vs_tumor.jpg)
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors | MD Anderson Cancer Center
![Adaptimmune on X: "Today, we proudly announce the initiation of a rolling biologics license application (BLA) for afami-cel, our first-gen engineered TCR T-cell therapy targeting MAGE-A4. Completion of the submission is planned Adaptimmune on X: "Today, we proudly announce the initiation of a rolling biologics license application (BLA) for afami-cel, our first-gen engineered TCR T-cell therapy targeting MAGE-A4. Completion of the submission is planned](https://pbs.twimg.com/media/FkrzEe0WAAcCdQ7.jpg:large)
Adaptimmune on X: "Today, we proudly announce the initiation of a rolling biologics license application (BLA) for afami-cel, our first-gen engineered TCR T-cell therapy targeting MAGE-A4. Completion of the submission is planned
![Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors :: Adaptimmune (ADAP) Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors :: Adaptimmune (ADAP)](https://images.newsfilecorp.com/files/8845/157280_25b4cbe27425cb7c_001.jpg)
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors :: Adaptimmune (ADAP)
![Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer | Journal for ImmunoTherapy of Cancer Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/10/1/e003581/F1.large.jpg)
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer | Journal for ImmunoTherapy of Cancer
![Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO :: Adaptimmune (ADAP) Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO :: Adaptimmune (ADAP)](https://images.newsfilecorp.com/files/8845/184696_2fea951a440f7873_001.jpg)
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO :: Adaptimmune (ADAP)
Adaptimmune on X: "NEWS: In this release, you will find a summary of the data that will be presented in our #AACR22 poster in which we present a large screening dataset examining
![Net Present Value Model: Adaptimmune Therapeutics Plc's ADPA-2M4CD8 - Market Research Reports & Consulting | GlobalData UK Ltd. Net Present Value Model: Adaptimmune Therapeutics Plc's ADPA-2M4CD8 - Market Research Reports & Consulting | GlobalData UK Ltd.](https://www.globaldata.com/store/wp-content/uploads/sites/2/2023/07/reportcover-LG5.webp)
Net Present Value Model: Adaptimmune Therapeutics Plc's ADPA-2M4CD8 - Market Research Reports & Consulting | GlobalData UK Ltd.
![Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial | Nature Medicine Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-02128-z/MediaObjects/41591_2022_2128_Fig4_HTML.png)